image
Healthcare - Biotechnology - NASDAQ - GB
$ 1.6
0.699 %
$ 426 M
Market Cap
-1.67
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one AUTL stock under the worst case scenario is HIDDEN Compared to the current market price of 1.6 USD, Autolus Therapeutics plc is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one AUTL stock under the base case scenario is HIDDEN Compared to the current market price of 1.6 USD, Autolus Therapeutics plc is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one AUTL stock under the best case scenario is HIDDEN Compared to the current market price of 1.6 USD, Autolus Therapeutics plc is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart AUTL

image
$5.0$5.0$4.5$4.5$4.0$4.0$3.5$3.5$3.0$3.0$2.5$2.5$2.0$2.0$1.5$1.5$1.0$1.0Nov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 Apr
FINANCIALS
10.1 M REVENUE
496.00%
-241 M OPERATING INCOME
-23.79%
-221 M NET INCOME
-5.89%
-206 M OPERATING CASH FLOW
-41.68%
-395 M INVESTING CASH FLOW
-3491.41%
590 M FINANCING CASH FLOW
66867.16%
29 K REVENUE
0.00%
-64.5 M OPERATING INCOME
5.01%
-27.6 M NET INCOME
66.37%
-37.9 M OPERATING CASH FLOW
50.57%
-384 M INVESTING CASH FLOW
-3900.30%
30 M FINANCING CASH FLOW
16120.00%
Balance Sheet Autolus Therapeutics plc
image
Current Assets 661 M
Cash & Short-Term Investments 588 M
Receivables 0
Other Current Assets 72.9 M
Non-Current Assets 122 M
Long-Term Investments 0
PP&E 105 M
Other Non-Current Assets 16.7 M
75.13 %9.31 %13.42 %Total Assets$782.7m
Current Liabilities 60.7 M
Accounts Payable 1.97 M
Short-Term Debt 3 M
Other Current Liabilities 55.8 M
Non-Current Liabilities 295 M
Long-Term Debt 49.6 M
Other Non-Current Liabilities 245 M
15.69 %13.96 %68.94 %Total Liabilities$355.4m
EFFICIENCY
Earnings Waterfall Autolus Therapeutics plc
image
Revenue 10.1 M
Cost Of Revenue 11.4 M
Gross Profit -1.27 M
Operating Expenses 240 M
Operating Income -241 M
Other Expenses -20.8 M
Net Income -221 M
50m50m00(50m)(50m)(100m)(100m)(150m)(150m)(200m)(200m)(250m)(250m)10m(11m)(1m)(240m)(241m)21m(221m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
-12.52% GROSS MARGIN
-12.52%
-2385.63% OPERATING MARGIN
-2385.63%
-2180.45% NET MARGIN
-2180.45%
-51.64% ROE
-51.64%
-28.19% ROA
-28.19%
-33.53% ROIC
-33.53%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Autolus Therapeutics plc
image
00(50m)(50m)(100m)(100m)(150m)(150m)(200m)(200m)(250m)(250m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -221 M
Depreciation & Amortization 7.72 M
Capital Expenditures 0
Stock-Based Compensation 15.5 M
Change in Working Capital 0
Others -8.61 M
Free Cash Flow -206 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Autolus Therapeutics plc
image
Wall Street analysts predict an average 1-year price target for AUTL of $8.7 , with forecasts ranging from a low of $7.6 to a high of $11 .
AUTL Lowest Price Target Wall Street Target
7.6 USD 375.00%
AUTL Average Price Target Wall Street Target
8.7 USD 443.75%
AUTL Highest Price Target Wall Street Target
11 USD 587.50%
Price
Max Price Target
Min Price Target
Average Price Target
11111010998877665544332211Jun '24Jun '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 15
6. Ownership
Insider Ownership Autolus Therapeutics plc
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Autolus Therapeutics to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025 LONDON, April 22, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today announces that it will release its first quarter 2025 financial results and operational highlights before open of US markets on Thursday, May 8, 2025. Management will host a conference call and webcast at 8:30 am EDT/13:30 pm BST to discuss the company's financial results and provide a general business update. globenewswire.com - 1 week ago
Autolus Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference LONDON, April 02, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces that the Company will participate in the 24th Annual Needham Virtual Healthcare Conference. Autolus Chief Executive Officer Dr. Christian Itin will present in a Fireside Chat on Wednesday, April 9, 2025 at 9:30am EDT / 14:30pm BST. globenewswire.com - 1 month ago
Autolus Therapeutics to Host R&D Investor Event on Wednesday, April 23, 2025 LONDON, April 01, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announced that the Company will host an R&D investor event on Wednesday, April 23, 2025 at 8:30am EDT / 13:30pm BST. Autolus will present an update on clinical pipeline programs, including plans to expand the obe-cel opportunity. globenewswire.com - 1 month ago
Autolus Therapeutics plc (AUTL) Q4 2024 Earnings Conference Call Transcript Autolus Therapeutics plc (NASDAQ:AUTL ) Q4 2024 Earnings Conference Call March 20, 2025 8:30 AM ET Company Participants Amanda Cray - IR Christian Itin - CEO Rob Dolski - CFO Conference Call Participants James Shin - Deutsche Bank Rajan Sharma - Goldman Sachs Asthika Goonewardene - Truist Matt Phipps - William Blair Gil Blum - Needham & Company Kelly Shi - Jefferies Yanan Zhu - Wells Fargo Jacob Mekhael - KBC Securities Simon Baker - Redburn Atlantic Operator Hello, ladies and gentlemen, and welcome to the Autolus Therapeutics Call to Discuss the Full Year 2024 Financial Results and Business Updates. As a reminder, this conference call is being recorded. seekingalpha.com - 1 month ago
Autolus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates AUCATZYL® (obecabtagene autoleucel) U.S. commercial launch progressing on track with 33 authorized treatment centers as of March 19, 2025, following US FDA approval on November 8, 2024 Obe-cel MHRA and EMA marketing authorizations expected in H2 2025 Initial six patients dosed in Phase 1 dose confirmation trial in Systemic Lupus Erythematosus (SLE) Company to provide clinical development program updates, including plans for expansion in autoimmune diseases, at R&D investor event to be held on April 23rd Conference call to be held today at 08:30 am EDT/12:30 pm GMT: conference call participants should pre-register using the link at the bottom of this press release LONDON, March 20, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces its operational and financial results for the full year ended December 31, 2024. “Reflecting on 2024, it was a year of strong execution leading to significant achievements for Autolus, including our strategic deal with BioNTech and corresponding financing to bolster our balance sheet, commencing GMP operations at our in-house CAR T manufacturing facility, and finishing the year with our first FDA approval and the commercial launch of AUCATZYL®,” said Dr. Christian Itin, Chief Executive Officer of Autolus. globenewswire.com - 1 month ago
Autolus Therapeutics to Report Fourth Quarter 2024 Financial Results and Host Conference Call on March 20, 2025 LONDON, March 06, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today announced that it will release its fourth quarter and full year 2024 financial results and operational highlights before open of US markets on Thursday, March 20, 2025. Management will host a conference call and webcast at 8:30 am EDT/12:30 pm GMT to discuss the company's financial results and provide a general business update. globenewswire.com - 1 month ago
Autolus Therapeutics to Participate in Upcoming Investor Conferences LONDON, March 05, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces that the Company will participate in two upcoming investor conferences. Jefferies Biotech on the Beach Summit Management to host investor meetingsDate: March 11, 2025Location: Miami, FL Leerink Global Biopharma Conference Fireside Chat PresentationDate and time: March 12, 2025; 8:40am EDT / 12:40pm GMTLocation: Miami, FLPresenter: Chief Executive Officer Dr. Christian Itin A webcast of the fireside chat will be available on the “Events” page in the “Investor Relations & Media” section of the Company's website at https://www.autolus.com/investor-relations-media/events/. globenewswire.com - 1 month ago
Autolus Therapeutics: Beaten Down, Cash Rich, Poised To Launch A CAR-T Cell Therapy Autolus Therapeutics' main focus is on obe-cel, a CAR T-cell therapy for B-cell ALL, with a strong likelihood of approval. AUTL has $657.1 million in cash, providing a cash runway of approximately 3 years, alleviating immediate financial concerns. The company faces significant competition in the CD19 CAR T-cell therapy market, making sales execution crucial for success. seekingalpha.com - 1 month ago
Autolus Therapeutics Presents Clinical Data Updates at the 2025 Tandem Meetings LONDON, Jan. 17, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces an oral presentation and three poster presentations accepted to the 2025 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, being held from February 12-15, 2025, in Hawai'i Convention Center, Honolulu, HI. “Building on our data presented at ASH in December, we come to Tandem with an updated health economic cost model directly comparing the cost of adverse events of AUCATZYL® versus other CAR-T cell therapies, which demonstrates that the shorter duration and lower incidence of CRS and ICANS contributes to a reduction in healthcare costs,” said Dr. Christian Itin, Chief Executive Officer of Autolus. globenewswire.com - 3 months ago
Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024 LONDON, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing next-generation programmed T cell therapies, announces an oral presentation and three poster presentations at the American Society of Hematology (ASH) Annual Meeting, being held from December 7-10, 2024, in San Diego. “Our oral presentation at ASH this year with data from the FELIX trial demonstrates that obe-cel treatment produces a high incidence of deep molecular remission in r/r adult ALL patients, which correlates with better outcomes and is associated with longer event free survival (EFS) and overall survival (OS),” said Dr. Christian Itin, Chief Executive Officer of Autolus. globenewswire.com - 4 months ago
AUCATZYL's Approval Positions Autolus Therapeutics Favorably In The CAR-T Market Autolus Therapeutics' AUCATZYL, approved by the FDA for relapsed/refractory B-cell ALL, shows strong potential despite safety concerns. The Company's Obe-cel family and oncology pipeline include multiple catalysts for 2025, expanding potential indications in autoimmune diseases and hematologic malignancies. AUTL's cash runway of 1.9 years and no financial debt provide a solid financial foundation to support AUCATZYL's commercialization and future growth. seekingalpha.com - 5 months ago
Autolus Therapeutics plc (AUTL) Q3 2024 Earnings Call Transcript Autolus Therapeutics plc (NASDAQ:AUTL ) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ET Company Participants Olivia Manser - Director-Investor Relations Christian Itin - Chief Executive Officer Rob Dolski - Chief Financial Officer Conference Call Participants James Shin - Deutsche Bank Matthew Phipps - William Blair Sebastiaan van der Schoot - VLK Hanze Zu - Jefferies Gil Blum - Needham & Company Jacob Mekhael - KBC Securities Operator Hello, ladies and gentlemen, and welcome to the Autolus Therapeutics Call to discuss its Third Quarter 2024 Financial Results and Business Updates. At this time, all participants are in a listen-only mode. seekingalpha.com - 5 months ago
8. Profile Summary

Autolus Therapeutics plc AUTL

image
COUNTRY GB
INDUSTRY Biotechnology
MARKET CAP $ 426 M
Dividend Yield 0.00%
Description Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
Contact The MediaWorks, London, W12 7FP https://www.autolus.com
IPO Date June 22, 2018
Employees 647
Officers Dr. Christopher Williams Chief Business Officer Mr. David Brochu Senior Vice President & Chief Technical Officer Mr. Robert F. Dolski Senior Vice President, Chief Financial Officer & Principal Accounting Officer Mr. Christopher Vann Senior Vice President & Chief Operating Officer Mr. Alexander Swan Senior Vice President & Chief Human Resources Officer Ms. Olivia Manser Director of Investor Relations Dr. Christian Martin Itin Ph.D. Chief Executive Officer & Director Mr. Alex Driggs Senior Vice President of Legal Affairs & General Counsel and Secretary Dr. Matthias Will M.D. Senior Vice President & Chief Development Officer Dr. Martin Pule M.D., MBBS Founder, Senior Vice President & Chief Scientific Officer